Beyond Meat Inc vs Cytokinetics Inc — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 49.3× Beyond Meat Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | CYTK | |
|---|---|---|
Market Cap | $215.41M | $10.63B |
Sector | Consumer Staples | Technology |
52-Week High | $3.62 | $87.26 |
52-Week Low | $0.42 | $34.31 |
Enterprise Value | $455.69M | $10.74B |
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.
The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
Trailing returns across standard periods
Latest headlines on both assets
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →